Abstract：【Objective】 To investigate the relationship between the expression of miR-143 and miR-33a in peripheral blood and the clinical prognosis of bladder cancer patients. 【Methods】 A total of 60 patients with bladder cancer admitted to our hospital from May 2017 to April 2021 (observation group) were selected, and 60 healthy volunteers who underwent physical examination in the same period were selected as the control group. The expression levels of miR-143 and miR-33a in the peripheral blood of the two groups of subjects and the expression levels of miR-143 and miR-33a in the peripheral blood of patients with different pathological characteristics were compared. The diagnostic value of miR-143 and miR-33a in the peripheral blood for bladder cancer was evaluated. The survival curves of bladder cancer patients with different expressions of miR-143 and miR-33a in the peripheral blood were compared. The relationship between the expression of miR-143 and miR-33a in the peripheral blood and the death risk of bladder cancer patients was analyzed.【Result】 The expression levels of miR-143 and miR-33a in the peripheral blood of the observation group were lower than those of the control group, and the difference was statistically significant (P<0.05). The expression levels of miR-143 and miR-33a in peripheral blood of patients with different clinical stages, degree of tissue differentiation, initial and recurrent stages, and presence or absence of distant metastasis were compared, and the differences were statistically significant (P<0.05). The area under the curve of miR-143 and miR-33a in the combined diagnosis of bladder cancer was 0.922, significantly higher than that of miR-143 and miR-33a (P<0.05). The postoperative 3-year survival rates of patients with low expression of miR-143 and miR-33a in peripheral blood were lower than those of patients with high expression of miR-143 and miR-33a in peripheral blood (P<0.05). The 3-year postoperative mortality risk of patients with low expression of miR-143 and miR-33a in peripheral blood is 4.550 times and 5.223 times higher than that of patients with high expression (P<0.05).【Conclusion】 The expression of miR-143 and miR-33a in the peripheral blood of patients with bladder cancer is down regulated, which is closely related to the pathological characteristics. The detection of their expression level is helpful to evaluate the prognosis of patients, and has high clinical value.
高永辉, 彭贝贝. 外周血miR-143、miR-33a表达与膀胱癌患者临床预后的相关性[J]. 医学临床研究, 2024, 41(1): 25-28.
GAO Yonghui, PENG Beibei. Correlation between the Expression of miR-143 and miR-33a in Peripheral Blood and the Clinical Prognosis of Bladder Cancer Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(1): 25-28.
[1] 白红松,寿建忠,周爱萍,等.外周血中性粒细胞与淋巴细胞比值在新辅助化疗指导下的肌层浸润性膀胱癌综合治疗中的意义[J].现代泌尿生殖肿瘤杂志,2021,13(4):204-209. [2] 卢俅,陈兵海.基于多重生物信息学分析对膀胱癌关键基因及其调控网络的研究[J].中国免疫学杂志,2021,37(15):1798-1803. [3] FAVIER A,ROCHER G,LARSEN A K, et al. MicroRNA as epigenetic modifiers in endometrial cancer: a systematic review[J].Cancers (Basel),2021,13(5):1137. [4] 邓益森,何宇辉,应文伟,等.膀胱癌患者尿液外泌体中miRNA差异表达谱及其生物信息学分析[J].现代肿瘤医学,2021,29(3):446-450. [5] 张钰,曹彩霞,牛海涛,等.血清LncRNA XIST与miR-33a在膀胱癌中的表达及临床意义[J].现代生物医学进展,2020,20(15):2962-2966. [6] 杨新选,任航.膀胱癌患者血清miR-143、miR-144和miR-145水平变化及临床意义[J].海南医学,2021,32(21):2725-2729. [7] 贺海蓉,李莉,冯敖梓,等.1990—2017年全球膀胱癌发病率和死亡率的研究[J].中国循证医学杂志,2020,20(11):1257-1265. [8] CATTO J W F,KHETRAPAL P, RICCIARDI F, et al. Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: A randomized clinical trial[J].JAMA,2022,327(21):2092-2103. [9] LIU T, LIU D, GUAN S W, et al. Diagnostic role of circulating MiR-21 in colorectal cancer:a update meta-analysis[J].Ann Med,2021,53(1):87-102. [10] DONKERS H, BEKKERS R, GALAAL K. Diagnostic value of microRNA panel in endometrial cancer: A systematic review[J].Oncotarget,2020,11(21):2010-2023. [11] LIU H F, ZHENG M L, ZHAO Y C, et al.miR-143 inhibits migration and invasion through regulating LASP1 in human esophageal cancer[J].Int J Clin Exp Pathol,2019,12(2):466-476. [12] LIESHOUT M H P,VOS A F,DESSING M C,et al.ASC and NLRP3 impair host defense during lethal pneumonia caused by serotype 3 Streptococcus pneumoniae in mice[J].Eur J Immunol,2018,48(1):66-79. [13] 王丽丽,崔艳歆,崔华硕.外周血miR-143、miR-33a水平与膀胱癌临床病理特征及化疗疗效的关系[J].分子诊断与治疗杂志,2022,14(6):966-969. [14] 王秋红,左书强,刘坤龙,等.肌层浸润性膀胱癌根治术患者的预后影响因素分析[J].实用癌症杂志,2022,37(1):111-113.
2024, Vol. 41 
